

Mail Today, Delhi

Monday 22nd September 2014, Page: 25

Width: 18.95 cms, Height: 8.78 cms, 44r, Ref: pmln.2014-09-22.37.72

PHOENIX OF PHARMA BUSINESS



Joaquin Duato, worldwide chairman, pharmaceuticals, J&J

JOAQUIN Duato, the low-key worldwide chairman, pharmaceuticals, Johnson & Johnson (J&J), feels that India will become an important hub for innovation in pharmaceutical research in the future.

"I believe that as the system matures, you are going to see India becoming an important player (in medical technology) as it is today in other areas of technology," says Duato, who has assumed charge of the roughly one-third pharmaceuticals arm of the \$75-billion J&J.

Duato's company puts its money where its mouth is. Speaking on helping Indian institutions carry on

research and development, Duato says the involvement of J&J isn't just for the sake of keeps. "I would say there are collaborations and research in collaboration with Indian universities in all sectors—not only in pharmaceuticals but also in medical devices," he says.

Given the fact that J&J is, in fact, the world's largest pharmaceutical and health care company, Duato's words might as well be prophetic.

By the way, Duato shares his first name with Hollywood actor Joaquin Phoenix, and has watched Phoenix's Oscar-nominated biopic of famous American singer Johnny Cash.

Joaquin Duato feels India will become an important hub for pharmaceutical research

R 22